

# *Macula Society Fluorescein Cases for 2008*

WEDNESDAY, MARCH 26, 2008

*Fluorescein Angiography/Retinal Case Conference*

**4:45 - 6:55 p.m. Chair: Lawrence A. Yannuzzi  
Moderator: William Mieler**

- 4:45 p.m. Anita Agarwal  
Mystery
- 4:50 p.m. J. Arevalo  
Unknown case
- 4:55 p.m. James Augsburger  
Optic Disc Lesion
- 5:00 p.m. Charles Barr  
Benign Concentric Macular Dystrophy
- 5:05 p.m. David Brown  
Cystoid Macular Edema Secondary to Paclitaxel
- 5:10 p.m. Gary Brown  
A Cost-Effective, No, Very Cost-effective Intervention
- 5:15 p.m. Tom Chang  
Unknown case
- 5:20 p.m. Michael Goldbaum  
Child with Hypopigmented Retinas
- 5:25 p.m. Michaella Goldstein  
Exudative Retinal Detachment
- 5:30 p.m. Justin Gottlieb  
Posterior Uveitis
- 5:35 p.m. Simon Harding  
Acute Maculopathy on a Madagascar Honeymoon
- 5:40 p.m. Nancy Holekamp  
Scotoma Formation after Exposure of Retinal Pigmented Epithelium to Indocyanine Green
- 5:45 p.m. Michael Klein  
Clinicopathologic Correlation of Retinal Angiomatous Proliferation in Age-related Macular Degeneration

# *Macula Society Fluorescein Cases for 2008*

WEDNESDAY, MARCH 26, 2008

**continued**

- 5:50 p.m. Noemi Lois  
Mystery Case
- 5:55 p.m. Andrew Lotery  
An Unusal Retinal Finding Resulting from the Iraq War
- 6:00 p.m. H. McDonald  
Unknown
- 6:05 p.m. William Mieler  
Unknown case
- 6:10 p.m. Jose Pulido  
URO
- 6:15 p.m. Jerry Shields  
Unknown Tumor Case
- 6:20 p.m. Jason Slakter  
Mystery Case
- 6:25 p.m. Richard Spaide  
Unknown
- 6:30 p.m. Janet Sunness  
Foveal Preservation in Geographic Atrophy Associated with  
AMD
- 6:35 p.m. Paul Tornambe  
A Dramatic Response in the Fellow Eye to Avastin in a Patient  
with Severe Bilateral PDR
- 6:40 p.m. Daniel Weidenthal  
Disabling Illness Caused by CSF Pressure Fluctuation
- 6:45 p.m. Lawrence Yannuzzi  
Mystery Case
- 6:50 p.m. Thomas Wolfensberger  
Weight Loss Before Vision Loss
- 6:55 p.m. **End session**

*2008*  
*Scientific Program*

**Thursday, Friday and Saturday**

**March 27 – 29, 2008**

**The Breakers**

**Palm Beach, Florida**

# THURSDAY, MARCH 27, 2008

## SESSION I

### Hereditary Retinal Disease/Miscellaneous Macular Diseases

*Chair: Edwin Stone*

*Moderator: Francisco Rodriguez*

- 7:30 a.m. A New Macular Dystrophy with Pigment Spots, Cysts, and Hemorrhage  
*Stephen R. Russell MD*
- 7:36 a.m. Cell-based Therapies for Retinal Degeneration  
*Peter J. Francis, MD, PhD*
- 7:45 a.m. Molecular Studies and Phenotype-Genotype Correlation in Female Carriers of a Colombian Family with X-Linked Juvenile Retinoschisis  
*Francisco J. Rodriguez, MD*
- 7:51 a.m. OCT Prevalence of CME in RP Patients Without Cystic Changes on Fundus Exam  
*Gerald A. Fishman, MD*
- 8:00 a.m. Two-color Pupillometry for Assessment of Inherited Retinal Disease  
*Edwin M. Stone, MD, PhD*
- 8:09 a.m. Unilateral Retinal Pigment Epithelium Dysgenesis  
*Salomon Y. Cohen, MD, PhD*
- 8:15 a.m. Retinal Effects of Erectile Dysfunction Drugs Taken on a Daily Basis  
*Michael Marmor, MD*

## SESSION II

### AMD Basic Science

*Chair: Bert Glaser*

*Moderator: Ivana Kim*

- 8:21 a.m. Vitreous Proteome in Wet Macular Degeneration vs. Non-neovascular Disease  
*Bert M. Glaser, MD*
- 8:30 a.m. Electrotaxis of Retinal Pigment Epithelial Cells: a Future Alternative in the Management of Atrophic Age-related Macular Degeneration and Other Retinal Diseases?  
*Noemi Lois, MD, PhD, FSCS(Ed)*
- 8:39 a.m. Selective Tubulin Inhibitors Show Evidence of Antiangiogenic and Angiolytic Effects in Animal Model of AMD  
*Craig M. Greven, MD*

- 8:48 a.m. Extracellular Matrix Transplants Improve RPE Survival on Aged Bruch's Membrane  
*Marco A. Zarbin, MD, PhD, FACS*

### SESSION III

#### AMD Genetics and Risk Factors

*Chair: Andrew Lotery*

*Moderator: Emily Chew*

- 8:54 a.m. Age-related Macular Degeneration and Risk of Coronary Heart Disease and Stroke: The Cardiovascular Health Study  
*Tien Y. Wong, MD, PhD*
- 9:03 a.m. Age-related Macular Degeneration is Associated with the HLA Cw\*0701 Genotype and Natural Killer Cell Receptor AA Haplotype  
*Andrew J. Lotery, MD, FRCOphth*
- 9:09 a.m. Genotype-phenotype Correlations for Exudative Age-related Macular Degeneration Associated with Homozygous HTRA1 and CFH Genotypes  
*Eric H. Souied, MD, PhD*
- 9:18 a.m. Correlation of Advanced Age-related Macular Degeneration Phenotypes with Variants in the LOC387715/ARMS2/HTRA1 Region  
*Ivana K. Kim, MD*
- 9:27 a.m. Gene and Environment Interaction in Age-related Macular Degeneration: Towards Customized Medicine  
*Kang Zhang, MD, PhD*
- 9:33 a.m. Reticular Pseudodrusen in Age-related Macular Degeneration (AMD)  
*Anita Agarwal, MD*
- 9:39 a.m. Ten-Year Estimated Progression Rates to Neovascular AMD and Central Geographic Atrophy from the Age-related Eye Disease Study (AREDS)  
*Emily Y. Chew, MD*

### SESSION IV

#### AMD Imaging

*Chair: David Brown*

*Moderator: Cynthia Toth*

- 9:45 a.m. Combined Cases of Polypoidal Choroidal Vasculopathy and Typical Age-related Macular Degeneration  
*Tomohiro Iida, MD*

- 9:51 a.m. Relationship Between Angiographic and OCT Parameters for Quantifying Choroidal Neovascular Lesions  
*SriniVas R. Sadda, MD*
- 9:57 a.m. Ranibizumab (LUCENTIS®) for Neovascular Age-related Macular Degeneration (AMD): Optical Coherence Tomography (OCT) vs. Visual Acuity (VA) Changes in PIER Study  
*David M. Brown, MD, FACS*
- 10:06 a.m. Photoreceptor Changes over Drusen Imaged with Spectral Domain OCT  
*Cynthia A. Toth, MD*
- 10:15 a.m. The Minnesota Grading System of Autofluorescence for Eyebank Eyes  
*Timothy W. Olsen, MD*
- 10:21 a.m. **Break**

## SESSION V

### AMD Visual Function/Psychosocial

*Chair: Usha Chakravarthy*

*Moderator: Simon Harding*

- 10:41 a.m. A Case Control Study of the Usefulness of Preferential Hyperacuity in Detecting Progression of Early to Late AMD  
*Usha Chakravarthy, MD, PhD*
- 10:47 a.m. Multicenter Study of a New Home Perimeter for CNV Detection  
*Michaella Goldstein, MD*
- 10:53 a.m. Patterns of Referral of AMD Patients for Low Vision Intervention in the Anti-VEGF Era  
*Janet S. Sunness, MD*
- 10:59 a.m. The Relationship Between Visual Acuity and Health-related Quality of Life. Report from the UK VPDT Cohort Study  
*Simon P. Harding, FRCOphth, MD*
- 11:05 a.m. **Presentation of the Donald M. Gass Medal**
- 11:10 a.m. **Rosenthal Foundation Lecture and Award Presentation**

## SESSION VI

### Surgery

*Chair: HR Macdonald*

*Moderator: Judy Kim*

- 11:30 a.m. Treatment of Lamellar Macular Holes Associated with Epiretinal Membranes  
*John T. Thompson, MD*

- 11:35 a.m. Prognostic Factors in Idiopathic Epiretinal Membrane Removal  
*Judy E. Kim, MD*
- 11:41 a.m. Unexplained Visual Loss Following Routine Vitrectomy for Epiretinal Membrane  
*H. Richard McDonald, MD*
- 11:47 a.m. **Five-minute Discussion on Previous Papers**
- 11:52 a.m. Specific Cleavage of the Posterior Vitreous-ILM Interface by Dispase: Modulation of Enzyme Activity by Calcium  
*Lucian V. Del Priore, MD, PhD*
- 12:01 p.m. 360° Retinotomy for the Treatment of Complex Retinal Detachment  
*Neelaksbi Bhagat, MD, MPH, FACS*
- 12:10 p.m. Maximum Visual Acuity Obtained from Repair of the Detachment Emanating from Retinoschisis  
*Harvey A. Lincoff, MD*
- 12:19 p.m. Endophthalmitis after 25- versus 20-Gauge Vitrectomy: A Multicenter Study  
*Harry W. Flynn, Jr. MD*

## SESSION VII

### Uveitis

*Chair: Rick Spaide*

*Moderator: Jose Pulido*

- 12:25 p.m. Initial Results of QuantiFERON-TB Gold Testing in Patients with Uveitis  
*Jose S. Pulido, MD, MS, MPH, MBA*
- 12:31 p.m. Photoreceptor Outer Segment Abnormalities as a Cause of Blind Spot Enlargement in Acute Zonal Occult Outer Retinopathy-Complex Diseases  
*Richard F. Spaide, MD*
- 12:40 p.m. Restored Photoreceptor Outer Segment Damage in MEWDS  
*Shoji Kishi, MD*
- 12:49 p.m. Analysis of Eight Major AMD-associated Alleles in Patients with Multifocal Choroiditis: Strong Association with Complement Factor H  
*K. Bailey Freund, MD*

## SESSION VIII

### Pharmacology-Treatment of Miscellaneous Diseases

- 12:58 p.m. Low Fluence Photodynamic Therapy in Chronic Central Serous Choroidopathy: Blind Randomized Clinical Trial of Efficacy and Safety  
*Francesco Boscia, MD*
- 1:07 p.m. Intravitreal Bevacizumab as a Salvage Treatment for ROP  
*Ruth Siegel, MD*
- 1:16 p.m. **Adjourn**

## FRIDAY, MARCH 28, 2008

## SESSION IX

### Basic Science-Miscellaneous

*Chair: Joan Miller*

*Moderator: David Zacks*

- 7:30 a.m. Modulation of VEGF Level in RPE Cells by Inhibition of Alpha V Integrins  
*Dov Weinberger, MD*
- 7:39 a.m. Endogenous Endostatin Inhibits Choroidal Neovascularization  
*Joan W. Miller, MD*
- 7:48 a.m. Pre-clinical Evaluation of Six Novel Dyes for Chromovitrectomy  
*Michel E. Farah, MD*
- 7:57 a.m. The X-linked Inhibitor of Apoptosis (XIAP) as a Photoreceptor Neuroprotectant During Periods of Retinal-RPE Separation  
*David N. Zacks, MD, PhD*
- 8:06 a.m. Expression Studies of Laser-Induced RPE Stress  
*Shalesh Kaushal, MD, PhD*
- 8:15 a.m. Clinical and Experimental Neuroglial Remodelling Following Resolution of Acute Macular Edema  
*Jose A. Sabel, MD*
- 8:21 a.m. RVM Analysis of Multifocal ERGs of Eyes in HIV-Positive Subjects without Infectious Retinitis Shows Deficiencies  
*Michael H. Goldbaum, MD*



## SESSION X

### Tumors

*Chair: Bill Harbour*

*Moderator: James Augsberger*

- 8:27 a.m. Ambient UVR Exposure and Risk of Death from Ocular Melanoma  
*Evangelos S. Gragoudas, MD*
- 8:36 a.m. A Clinically and Prognostically Relevant Molecular Classification of Uveal Melanoma  
*J. William Harbour, MD*
- 8:45 a.m. Quality of Evidence about Effectiveness of Treatments for Metastatic Uveal Melanoma  
*James J. Augsburger, MD*
- 8:54 a.m. Targeting Regional Hypoxia Enhances Retinoblastoma Tumor Control: Use of 2-DG as a Novel Therapeutic Strategy  
*Timothy G. Murray, MD, MBA, FACS*

## SESSION XI

### Neovascular AMD Pharmacology Monotherapy Part 1

*Chair: Neil Bressler*

*Moderator: Carl Regillo*

- 9:03 a.m. Endophthalmitis Following Anti-VEGF Injections in a Retinal Practice Setting  
*Michael J. Elman MD*
- 9:08 a.m. A Phase I Open-Label Study of Single and Repeated Doses of Intravitreal JSM6427, a Small Molecule Integrin Antagonist, in Neovascular Age-related Macular Degeneration  
*Anthony P. Adamis, MD*
- 9:13 a.m. Primary Intravitreal Bevacizumab (Avastin) for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration: Results of the Pan-American Collaborative Retina Study Group at 12-months Follow-up  
*J. Fernando Arevalo, MD, FACS*
- 9:18 a.m. Intravitreal Bevacizumab in the Management of Peripapillary Subretinal Neovascular Membranes  
*Mandi D. Conway, MD*
- 9:23 a.m. A Phase 2, Randomized, Controlled Dose-Ranging and Interval-Ranging Study of Intravitreal VEGF Trap in Patients with Neovascular Age-related Macular Degeneration  
*Quan Dong Nguyen, MD, MSc*

- 9:29 a.m. A Phase 2, Randomized, Controlled Dose- and Interval-Ranging Study of Intravitreal VEGF Trap in Patients with Neovascular Age-related Macular Degeneration: OCT and Fluorescein Angiographic Outcomes  
*Jason S. Slakter, MD*
- 9:35 a.m. Comparison of Lesion Characteristics between Ranibizumab (LUCENTIS®) Treated Patients who Lost or Gained Visual Acuity (VA) in the MARINA and ANCHOR Trials  
*Philip J. Rosenfeld, MD, PhD*
- 9:41 a.m. **Nine-minute Discussion on Previous Papers**
- 9:50 a.m. **Presentation of the Arnall Patz Medal**
- 9:55 a.m. **W. Richard Green Lecture and Presentation of Award**
- 10:15 a.m. **Break**

### **Neovascular AMD Pharmacology Monotherapy Part 2**

*Chair: Anthony Adamis*

*Moderator: Jason Slakter*

- 10:35 a.m. Seemingly Paradoxical Results from ANCHOR: Relationship of Changes between Visual Acuity and Patient-reported Visual Function Following AMD Treatment  
*Neil M. Bressler, MD*
- 10:41 a.m. Ranibizumab (LUCENTIS®) for Neovascular Age-related Macular Degeneration (AMD): Two-year Angiographic Results of PIER Study  
*Allen C. Ho, MD*
- 10:47 a.m. Ranibizumab in Neovascular Age-related Macular Degeneration (AMD): Crossover/ Rollover Treatment Effects in PIER Study  
*Carl D. Regillo, MD*
- 10:52 a.m. Ranibizumab (LUCENTIS®) Safety in Previously Treated and Newly Diagnosed Patients with Neovascular Age-related Macular Degeneration (AMD): The SAILOR Study  
*Elias Reichel, MD*
- 10:58 a.m. Comparison Study of Remission Intervals in Patients Treated with Ranibizumab vs. Bevacizumab for Neovascular AMD  
*Tom S. Chang, MD*
- 11:03 a.m. Treatment of Non-vascularized Pigment Epithelial Detachments with Ranibizumab  
*Herbert L. Cantrill, MD*
- 11:09 a.m. **Ten-minute Discussion on Previous Papers**

## SESSION XII

### Neovascular AMD Pharmacology Combination Therapy

*Chair: Paul Tornambe*

*Moderator: Michael Potter*

- 11:19 a.m. Combination Photodynamic Therapy and Bevacizumab Reduces the Retreatment Rate in a Randomized, Controlled, Double-Masked Study of Low and Very Low Fluence Laser in Age-Related Macular Degeneration  
*Michael J. Potter, MD, FRCSC*
- 11:24 a.m. Triple Therapy for the Treatment of Wet AMD  
*Albert J. Augustin, MD*
- 11:30 a.m. Combination Therapy with Verteporfin PDT, anti-VEGF Agents, and Corticosteroids: Results of Two Visudyne Registry Databases  
*William F. Mieler, MD*
- 11:36 a.m. Triple Therapy for Choroidal Neovascularization Due to Age-related Macular Degeneration. Ranibizumab, Ixtrascleral Triamcinolone Acetonide, and Verteporfin PDT. Early Vascular Changes  
*Paolo Lanzetta, MD*
- 11:41 a.m. Combined Intravitreal Bevacizumab and Triamcinolone for Exudative Age-related Macular Degeneration  
*Jost B. Jonas, MD*
- 11:46 a.m. Pegaptanib Sodium as Maintenance in Patients with Neovascular AMD: Interim Results of the Level Study  
*Thomas R. Friberg, MS, MD*
- 11:51 a.m. A Study to Evaluate the Safety and Feasibility of Radiotherapy and Bevacizumab (Avastin®) for the Treatment of Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)  
*Jeffrey S. Heier, MD*
- 11:57 a.m. **Ten-minute Discussion of Previous Papers**

## SESSION XIII

### Neovascular AMD Pharmacology–Miscellaneous

*Chair: Gary Brown*

*Moderator: Michael Klein*

- 12:07 p.m. The Comparative Effectiveness of Vitreoretinal Interventions  
*Gary C. Brown, MD, MBA*
- 12:16 p.m. Anterior Chamber VEGF Levels in Health and Disease  
*Paul Tornambe, MD*

- 12:25 p.m. Sham vs. No-Treatment Controls in Randomized Clinical Trials of Treatments of Neovascular Age-related Macular Degeneration  
*Barbara S. Hawkins, PhD*
- 12:34 p.m. Intravitreal Ranibizumab for the Management of Choroidal Neovascularization in Angioid Streaks  
*Anita Leys, MD*
- 12:40 p.m. Clinicopathologic Correlation of Retinal Angiomatous Proliferation in Age-related Macular Degeneration  
*Michael Klein, MD*
- 12:46 p.m. **Adjourn**

## SATURDAY, MARCH 29, 2008

### SESSION XIV

#### Basic Science-Drug Delivery

*Chair: Lawrence Morse*

*Moderator: Baruch Kupperman*

- 8:00 a.m. In Vitro Retinal Toxicity of Various Solubilized Steroids  
*Baruch D. Kuppermann, MD, PhD*
- 8:09 a.m. Ocular and Systemic Pharmacokinetics of an Intravitreal Dexamethasone Posterior Segment Drug Delivery System  
*Anat Loewenstein, MD, MHA*
- 8:18 a.m. Pharmacogenetic Microarray Analysis of Mouse Retinal Gene Expression Following Intravitreal Injection of Triamcinolone and VEGF  
*Lawrence S. Morse, MD, PhD*

### SESSION XV

#### Basic Science Imaging

- 8:24 a.m. Normal Data Ranges for Retinal Sensitivity, Retinal Thickness, and RNFL Thickness  
*Felix N. Sabates, MD, FACS*
- 8:30 a.m. Observation of Erythrocyte Dynamics in the Retinal Capillaries and Choriocapillaris Using ICG-loaded Erythrocyte Ghost Cells  
*Robert W. Flower, DRHC*
- 8:39 a.m. Ultra-wide Field Imaging in CMV Retinitis  
*Mathew W. MacCumber, MD, PhD*
- 8:45 a.m. Three-dimensional Imaging of PO<sub>2</sub> in the Choroidal and Retinal Blood Vessels  
*Norman P. Blair, MD*

## SESSION XVI

### Non-diabetic Retinal Vascular Disease-Miscellaneous

*Chair: Lee Jampol*

*Moderator: Barbara Blodi*

- 8:54 a.m. Idiopathic Perifoveal Telangiectasia: New Observations in this Distinct Clinical Retinal Vascular Abnormality  
*Lawrence A. Yannuzzi, MD*
- 9:03 a.m. Junctional Primary Retinal Telangiectasies  
*Leonidas Zografos, MD*
- 9:12 a.m. New Indications for Anti-VEGF Therapy: Retinal Arterial Macroaneurysm (RAM) and Nonarteritic Ischemic Optic Neuropathy (NAION)  
*Naresh Mandava, MD*

## SESSION XVII

### Retinal Venous Occlusive Disease

- 9:21 a.m. Hypoxia Tolerance and Retinal Vein Occlusion  
*Martine Mauget-Faysse, MD*
- 9:27 a.m. Clinic vs. Reading Center Evaluation of Dense Retinal Hemorrhage at Baseline in the SCORE Branch Retinal Vein Occlusion Study  
*Barbara A. Blodi, MD*
- 9:36 a.m. Intraocular Concentration of Growth Factors and Cytokines in Antiangiogenic Therapy of Retinal Vein Occlusion  
*Ursula Schmidt-Erfurth, MD*
- 9:42 a.m. **Break**

## SESSION XVIII

### Diabetic Retinopathy/Diabetic Macular Edema Part 1

*Chair: Lloyd Aiello*

*Moderator: Victor Chong*

- 10:02 a.m. Optical Coherence Tomography Features Predictive of Visual Outcomes after Intravitreal Bevacizumab Injection for Diabetic Macular Edema  
*Oh Woong Kwon, MD, PhD*
- 10:08 a.m. Intravitreal Bevacizumab for the Treatment of Refractory Diabetic Macular Edema  
*Kevin J. Blinder, MD*
- 10:13 a.m. A Phase 2 Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema  
*Ingrid U. Scott, MD, MPH*

- 10:18 a.m. Agreement Between Clinician and Reading Center Gradings of Diabetic Retinopathy Severity Level at Baseline in a Phase 2 Study of Intravitreal Bevacizumab for Diabetic Macular Edema  
*Susan B. Bressler, MD*
- 10:23 a.m. A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Laser Photocoagulation for Diabetic Macular Edema: Study Design and Baseline Characteristics  
*Michael S. Ip, MD*
- 10:28 a.m. Optical Coherence Tomography Measurements and Analysis Methods in Optical Coherence Tomography Studies of Diabetic Macular Edema  
*Frederick L. Ferris, MD*
- 10:34 a.m. Retinal Hydration Assessment with Optical Coherence Tomography  
*Tongalp H. Tezel, MD*
- 10:40 a.m. **Ten-minute Discussion on Previous Papers**

### **Diabetic Retinopathy/Diabetic Macular Edema Part 2**

*Chair: Rick Ferris*

*Moderator: Michael Ip*

- 10:50 a.m. Effects of Dilation on Visual Acuity Obtained by Electronic-ETDRS Visual Acuity Testing (EVA) in Diabetic Patients  
*Lloyd P. Aiello, MD, PhD*
- 10:59 a.m. Statin-mediated Inhibition of VEGF Expression  
*Dennis M. Marcus, MD*
- 11:04 a.m. A Diabetic Retinopathy Telemedicine-Based Screening and Treatment Program in Guanajuato, Mexico  
*George H. Bresnick, MD, MPA*
- 11:09 a.m. Clinically Significant Diabetic Macular Edema: Structural and Functional Parameters  
*Edoardo Midena, MD*
- 11:15 a.m. Micropulse vs. Green Laser Therapy in Diabetic Macular Edema  
*Victor Chong, MD*
- 11:20 a.m. Formation of Microintraretinal Break Induces Serous Retinal Detachment in Diabetic Macular Edema  
*Nagahisa Yoshimura, MD, PhD*
- 11:26 a.m. **Ten-minute Discussion on Previous Papers**
- 11:36 a.m. **Adjourn**